Helius Medical Technologies, Inc. Announces PoNS® Is Now Available on the Veterans Affairs (VA) Federal Supply Schedule (FSS) and General Services Administration (GSA) Advantage Contracts
NEWTOWN, Pa., May 20, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced the Company’s Portable Neuromodulation Stimulator (PoNS®) device has been approved for inclusion on Lovell Government Services’ (“Lovell”) Veterans Affairs (VA) Federal Supply Schedule (FSS) and General Services Administration (GSA) Advantage contracts.
- The contract award number #V797D-50450 enables the VA and other Federal entities to purchase PoNS at pre-approved pricing via the VA’s FSS Medical Equipment and Surgical (Med/Surg) Contract at VA National Acquisition Center MedSurg Catalog and via the GSA Advantage online catalog at GSA Advantage .
- The PoNS system, Item # S1-001-02, is priced at $23,843.72 and the PoNS mouthpiece, Item # M1-001 is priced at $7,344.97.
- PoNS is indicated in the U.S. for use as a short-term treatment of gait deficit in adults with mild-to-moderate symptoms from MS when used in conjunction with physical therapy.
- The VA estimates that between 55,000 and 70,000 veterans in the U.S. live with MS.
“We’re proud that PoNS is now available to veterans and Federal employees under the VA Healthcare System.